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OBJECTIVE — Thestudy’sgoalwastoevaluatetheperformanceofA1Candfastingcapillary
blood glucose (FCG) tests as mass screening tools for diabetes and pre-diabetes, as determined
by the standard oral glucose tolerance test (OGTT).
RESEARCH DESIGN AND METHODS — Data from 2,332 individuals aged 35–74
yearswhoparticipatedinapopulation-basedcross-sectionaldiabetessurveyinQingdao,China,
were analyzed. A 2-h 75-g OGTT was used to diagnose diabetes. The performance of A1C and
FCG was evaluated against the results of the OGTTs by using receiver operating characteristic
curve (ROC) analysis.
RESULTS — The prevalence of newly diagnosed diabetes and pre-diabetes (impaired fasting
glucose and/or impaired glucose tolerance) was 11.9 and 29.5%, respectively. For subjects with
newly diagnosed diabetes, the area under the ROC curve was 0.67 for A1C and 0.77 for FCG
(P  0.01) in men and 0.67 and 0.75 (P  0.01) in women, whereas for pre-diabetes, these
values were 0.47 and 0.64 (P  0.001) in men and 0.51 and 0.65 (P  0.001) in women. At the
optimal A1C cutoff point of 5.6% for newly diagnosed diabetes, sensitivities (speciﬁcities)
were 64.4% (61.6%) for men and 62.3% (63.3%) for women.
CONCLUSIONS — As a screening tool for newly diagnosed diabetes and pre-diabetes, the
FCG measurement performed better than A1C in this general Chinese population.
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T
ype 2 diabetes has become a serious
public health threat worldwide, and
itleadstoincreasedprematuremor-
tality and morbidity including blindness,
renal failure, amputation, and cardiovas-
cular disease. Diabetes and its complica-
tions may occur several years before a
clinicaldiagnosisismade.Massscreening
for diabetes can lead to an early diagnosis
and timely treatment or intervention,
whichhavebeenshowntoreducediabetes-
associated complications and to prevent
or delay the onset of diabetes per se. Cur-
rently, diabetes and pre-diabetes are clas-
siﬁed according to the 2-h 75-g oral
glucose tolerance test (OGTT) (1), which
has been considered as a standard diag-
nostic criterion for diabetes for several
decades. However, there are several
limitations associated with the OGTT.
These limitations include the uncertainty
ofthefastingstage,thepoorreproducibil-
ity of the 2-h glucose tests (2), and the
poor concordance between the fasting
plasma glucose (FPG) and the 2-h plasma
glucose levels (3).
The capillary blood glucose test is a
point-of-care determination and involves
only one ﬁnger prick. Because it is easy to
use and cheap, it is applied as a ﬁrst-step
screening test for mass screening of sub-
jects in either the fasting (4,5) or the ran-
dom (4) state. In contrast, A1C is the
mean of the long-term glucose level and
does not require the subject to be in a
fasting state with only one blood sample
drawn.Itisusedtomonitorglucoselevels
in diabetic individuals who have received
antihyperglycemictreatment.Becausethe
A1C test is less standard and relatively
expensive, it is not widely available. Con-
sequently, its use in mass screening has
been limited. Data on the performance of
the A1C test in mass screening for diabe-
tes are still lacking. In the light of the re-
cent development in standardizing the
method of A1C measurement (6), the
A1C test has been adopted as a diagnostic
criterion for diabetes (7). To evaluate the
performance of the A1C as a mass screen-
ing tool for diabetes as determined by
OGTTs in a general population and to
compare its performance with that of the
FCG test, data from a population-based
study in Qingdao, China, were analyzed.
RESEARCH DESIGN AND
METHODS— A population-based
cross-sectional diabetes survey was con-
ducted in Qingdao, China, in 2006. A
stratiﬁed, random cluster sampling
method was used to recruit a representa-
tive sample of those in the general popu-
lationwhohadlivedinQingdaocityforat
least5years.Thesurveywasconductedin
threeurbanandthreeruraladministrative
areas. Five resident communities from
each area with 200–250 individuals from
eachcommunitywererandomlyselected.
A total of 6,100 individuals aged 35–74
years were invited to participate in the
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response rate of 87.8%. Among 5,355
participants, 4,808 individuals who did
nothaveapriorhistoryofdiabetesunder-
went either FPG and/or 2-h plasma glu-
cose tests, and 4,203 (87.4%) underwent
A1C and 4,371 (90.9%) FCG tests. For
data analysis strict inclusion criteria were
applied: 1) undiagnosed diabetes identi-
ﬁed based on both FPG and 2-h plasma
glucose criteria; 2) data for both A1C and
FCG; and 3) no data missing for BMI,
waist circumference, and blood pressure.
A total of 2,332 (986 men and 1,346
women) individuals met the strict inclu-
sion criteria. By using the strict inclusion
criteria, we were able to correctly classify
diabetes status and to compare A1C with
FCG, but at the cost of reducing the sam-
ple size by 51.5% (2,476 of 4,808). To
check whether this strategy biased the re-
sults, a sensitivity analysis was performed
including all individuals with either A1C
(n  4,203) or FCG (n  4,371) test val-
ues regardless of missing data for either
FPG or 2-h plasma glucose. Undiagnosed
diabetes was, thus, classiﬁed according to
either FPG or 2-h plasma glucose criteria
in the sensitivity analysis. The survey was
approved by the Qingdao Municipal
Health Bureau and the local ethics com-
mittee, and informed consent was ob-
tained from all participants.
Participants were interviewed by
traineddoctorsornursesinthelocalcom-
munity clinics. Height and weight were
measured with the participants wearing
only light clothes and without shoes.
Waist circumference was measured at the
middlepointbetweentheribcageandtop
of the iliac crest to the nearest 0.1 cm.
Three consecutive blood pressure read-
ings were recorded at least 30 s apart.
Theyweretakenfromtheupperrightarm
of seated individuals, and the mean of the
three readings was used in the data anal-
ysis. BMI was calculated as weight in ki-
logramsdividedbythesquareofheightin
meters.
Afteranovernightfastofatleast10h,
surveyparticipantsintheirrespectivesur-
vey sites were given the FCG test over the
0700–0930 period, using a Bayer Ascen-
sia BRIO blood glucose monitoring sys-
tem that was calibrated to give capillary
plasma/serum glucose equivalent results
(Bayer HealthCare Company, Shanghai,
China). A standard OGTT was also per-
formed on the same day over the 0700–
1130 period, and blood samples for
glucose determinations were collected
from the antecubital vein into a vacuum
tube containing sodium ﬂuoride. All
blood samples were analyzed in the cen-
tral laboratory of Hiser Medical Center.
An Olympus AU system (Olympus, To-
kyo, Japan) was used for plasma glucose,
A1C, serum total cholesterol, triglycer-
ides, and HDL cholesterol levels. Plasma
glucose levels were determined using the
glucose oxidase method. A1C was mea-
sured using an immunoturbidimetry
method (Tina-qu.a A1C HIT 917 large;
Roche Diagnostics). The A1C concentra-
tion was calculated by using the formula
provided by Roche Diagnostics: [calcu-
lated A1C (%)  0.81  A1C (test re-
sult)  2.39] to match the values with
those found in a conventional high-
performance liquid chromatography
method. The calculated A1C was subse-
quently used in the data analysis. The ref-
erence range for the calculated A1C was
4.3–5.8%. Fasting insulin concentration
was measured in 1,636 individuals using
the chemiluminescence immunoassay
method (Abbott AxSym). The homeosta-
sis model assessment of insulin resistance
(HOMA-IR) was calculated using the for-
mula [HOMA-IR  fasting insulin (mi-
cro-international units per milliliter) 
FPG (millimoles per liter)/22.5], and the
homeostasis model assessment of -cell
function (HOMA-B) was calculated using
the formula {HOMA-B  20  fasting
insulin [micro-international units per
milliliter]/[FPG (millimoles per liter) 
3.5]} (8).
Previously diagnosed diabetes was
deﬁned as self-report of diabetes diag-
nosed by a doctor and/or on information
on treatment, and subjects with diag-
nosed diabetes were excluded from the
analysis. According to the World Health
Organization deﬁnition (1), newly diag-
nosed diabetes is deﬁned as having either
FPG 7.0 mmol/l and/or 2-h plasma glu-
cose 11.1 mmol/l. IGT is deﬁned as
having FPG 7.0 mmol/l and 2-h plasma
glucose7.8mmol/land2-hplasmaglu-
cose 11.1 mmol/l. Impaired fasting glu-
cose (IFG) is deﬁned as having FPG 6.1
mmol/l and FPG 7.0 mmol/l and 2-h
plasma glucose 7.8 mmol/l. Normal
glucose tolerance (NGT) is deﬁned as
FPG 6.1 mmol/l and 2-h plasma glu-
cose 7.8 mmol/l.
Statistical analysis
Statistical analysis was performed using
SPSS for Windows 15.0 (SPSS, Chicago,
IL) and STATA 9.1 (StataCorp, College
Station, TX). Continuous variables are
presented as means (95% CI), and cate-
goricaldataaregivenasnumber(percent-
age). Correlations between variables were
assessed by Pearson correlation coefﬁ-
cient. The differences between the means
of the groups were tested using a univar-
iate general linear model with adjust-
ments for age, and categorical data were
analyzed by using the 
2 test. The sen-
sitivity and speciﬁcity of the A1C and FCG
cutoff values for detecting newly diag-
noseddiabetes,pre-diabetes,ornewlydi-
agnosed diabetes plus pre-diabetes based
on the OGTT response were calculated.
The receiver operating characteristic
(ROC) curve was obtained by plotting
sensitivity against 1  speciﬁcity for each
cutoff value. The optimal cutoff point
was identiﬁed as the coordinate closest
to the y intercept (0,1) of the ROC
curve, and at this point, the sum of the
sensitivity and the speciﬁcity is maxi-
mal. Diagnostic accuracy was assessed
by the area under the curve (AUC) (9).
RESULTS— The respective preva-
lence of pre-diabetes and newly diag-
nosed diabetes among the participants
was 29.5 and 11.9%. Individuals of both
sexes with pre-diabetes and newly diag-
nosed diabetes were older, more obese,
hypertensive, dyslipidemic, and insulin
resistant and had poorer -cell function
(estimated by HOMA-B) compared with
individuals with NGT (Table 1). The cor-
relation coefﬁcients of the A1C with FPG
(0.57) and 2-h plasma glucose (0.61)
were higher in diabetic individuals than
in nondiabetic individuals (0.32 and
0.001, respectively).
As expected, diabetic individuals of
both sexes with A1C 6.5% had higher
meanFPGor2-hplasmaglucoseandalso
poorer -cell function than diabetic indi-
viduals with A1C 6.5%. However, this
was not the case in the nondiabetic indi-
viduals (Table 2). Among nondiabetic in-
dividuals, participants of both sexes with
A1C 6.5% had a lower prevalence of
IGT and/or IFG and lower mean FPG and
triglycerides than those with A1C 6.5%
(Table 2).
The AUC was lower for A1C than for
FCG for detecting newly diagnosed dia-
betes (0.67 vs. 0.77, P  0.01, in men;
and 0.67 vs. 0.75, P  0.01, in women)
and pre-diabetes (0.47 vs. 0.64, P 
0.001, in men; and 0.51 vs. 0.65, P 
0.001, in women) (Fig. 1). Moreover, for
newly diagnosed diabetes plus pre-
diabetes, the AUCs for A1C and FCG val-
ueswere0.53vs.0.69inmen(P0.001)
and 0.55 vs. 0.68 in women (P  0.001).
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ple with pre-diabetes from those with
NGT. The chance-corrected proportion
agreement () for classiﬁcation of diabe-
tes between the criteria of the OGTT and
theA1Cof6.5%thatarerecommended
by the International Expert Committee
(7) was 0.20 in men and 0.14 in women.
The optimal A1C cutoff point for newly
diagnosed diabetes in this study popula-
tion at 5.6% was lower than the recom-
mended value of 6.5%. At the optimal
A1C cutoff point of 5.6% for newly diag-
nosed diabetes, the sensitivity was 64.4%
in men and 62.3% in women, whereas it
was 72.0 and 65.1% at the optimal FCG
cutoffpointof6.3mmol/lformenand6.6
mmol/l for women (Table 3). Using the
recommended diagnostic value of 6.5%
for A1C (7), the sensitivity for newly di-
agnosed diabetes was 30% in both men
and women. The optimal FCG cutoff
value and the corresponding sensitivity
for pre-diabetes and pre-diabetes plus
newly diagnosed diabetes are shown in
Table 3.
To check whether the results were bi-
ased by excluding half of the survey par-
ticipants from the data analyses, a
sensitivity analysis was made using the
maximum number of participants for ei-
ther A1C or FCG. For undiagnosed dia-
betes, an AUC of 0.67 (95% CI 0.63–
0.72) in men and 0.70 (0.67–0.73) in
women for A1C and 0.78 (0.74–0.81) in
men and 0.76 (0.73–0.79) in women for
FCG was obtained, which did not differ
from the results presented in Fig. 1. The
groupwhometthestrictinclusioncriteria
Table 1—Characteristics of male and female subjects stratiﬁed by glucose tolerance status deﬁned according to both FPG and 2-h plasma
glucose level
All
Normal: FPG 6.1
mmol/l and 2-h PG
7.8 mmol/l
Pre-diabetes: FPG 6.1–6.9
mmol/l and/or 2-h PG
7.8–11.0 mmol/l
Undiagnosed diabetes: FPG 7.0
mmol/l and/or 2-h PG 11.1
mmol/l
Male subjects
n (%) 986 588 (59.6) 266 (27.0) 132 (13.4)
Age (years) 49.5 (48.950.2) 48.1 (47.348.9) 51.2 (50.052.4)* 52.6 (50.954.3)*
Waist circumference (cm) 87.2 (86.687.8) 85.6 (84.986.4) 89.6 (88.590.7)* 89.1 (87.590.7)*
BMI (kg/m
2) 25.7 (25.525.8) 25.2 (24.925.4) 26.4 (26.126.8)* 26.3 (25.826.8)*
Blood pressure (mmHg)
Systolic 134 (133135) 132 (130133) 136 (134138)† 138 (135141)†
Diastolic 87 (8788) 86 (8687) 88 (8790) 90 (8792)‡
Plasma glucose (mmol/l)
Fasting 5.7 (5.65.8) 5.1 (5.05.2) 5.9 (5.86.1)* 7.9 (7.78.1)*
2-h 7.1 (6.97.3) 5.7 (5.55.9) 7.5 (7.27.8)* 12.4 (11.912.8)*
A1C (%) 5.7 (5.75.8) 5.6 (5.65.7) 5.5 (5.45.6) 6.4 (6.36.5)*
A1C 6.5% 116 (11.8) 67 (11.4) 12 (4.5)† 37 (28.0)*
FCG (mmol/l) 6.1 (6.06.1) 5.7 (5.65.8) 6.2 (6.06.3)* 7.4 (7.27.6)*
Cholesterol (mmol/l) 5.3 (5.25.3) 5.2 (5.15.2) 5.3 (5.25.5) 5.5 (5.45.7)*
Triglycerides (mmol/l) 1.2 (1.21.2) 1.1 (1.01.1) 1.4 (1.31.5)* 1.5 (1.41.6)*
HDL cholesterol (mmol/l) 1.64 (1.611.67) 1.68 (1.641.72) 1.55 (1.491.60)* 1.61 (1.531.69)
HOMA-IR§ 1.1 (1.01.1) 0.8 (0.80.9) 1.5 (1.31.7)* 1.7 (1.42.0)*
HOMA-B§ 55.1 (51.758.7) 60.9 (56.265.9) 53.9 (47.661.0) 34.6 (28.941.4)*
Female subjects
n (%) 1,346 777 (57.7) 423 (31.4) 146 (10.8)
Age (years) 49.3 (48.849.8) 47.2 (46.647.9) 51.4 (50.552.3)* 54.4 (52.955.9)*
Waist circumference (cm) 81.9 (81.582.4) 80.8 (80.281.4) 83.1 (82.283.9)* 84.6 (83.286.1)*
BMI (kg/m
2) 25.8 (25.626.0) 25.3 (25.125.6) 26.4 (26.026.7)* 26.8 (26.227.4)*
Blood pressure (mmHg)
Systolic 132 (131133) 128 (127130) 137 (135139)* 138 (135141)*
Diastolic 84 (8485) 83 (8283) 86 (8588)* 87 (8589)*
Plasma glucose (mmol/l)
Fasting 5.6 (5.65.7) 5.2 (5.15.2) 5.8 (5.85.9)* 7.4 (7.37.6)*
2-h 7.3 (7.27.5) 6.0 (5.96.1) 7.9 (7.78.1)* 12.8 (12.513.2)*
A1C (%) 5.6 (5.65.6) 5.6 (5.55.6) 5.5 (5.45.6) 6.1 (6.06.2)*
A1C 6.5% 137 (10.2) 82 (10.6) 23 (5.4)† 32 (21.9)*
FCG (mmol/l) 6.1 (6.06.1) 5.7 (5.65.8) 6.2 (6.16.3)* 7.4 (7.27.6)*
Cholesterol (mmol/l) 5.2 (5.25.3) 5.2 (5.15.2) 5.3 (5.25.3) 5.5 (5.45.7)*
Triglycerides (mmol/l)§ 1.1 (1.01.1) 1.0 (1.01.0) 1.1 (1.01.1)‡ 1.4 (1.31.5)*
HDL cholesterol (mmol/l) 1.68 (1.651.70) 1.73 (1.701.77) 1.61 (1.571.65)* 1.57 (1.501.65)*
HOMA-IR§ 1.4 (1.31.5) 1.2 (1.11.3) 1.7 (1.61.8)* 2.3 (2.02.6)*
HOMA-B§ 67.9 (64.771.3) 74.4 (69.979.2) 65.0 (59.570.9)‡ 44.7 (38.452.1)*
Dataareage-adjustedmeans(95%CI)orn(%).*P0.001;†P0.01;‡P0.05,forthedifferencebetweentheindexedandthenormalcategoryusingaunivariate
general linear model for continuous data and 
2 test for categorical data. §Geometric mean (95% CI). With missing data.
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with regard to mean age, BMI, and blood
pressure, but the former consisted of
more men (42.3 vs. 35.6%, P  0.001)
and had a slightly higher prevalence of
undiagnosed diabetes (11.9 vs. 10.1%,
P  0.04) than the latter as expected.
CONCLUSIONS — In this popula-
tion-based study, the FCG test performed
better than A1C in ability to identify
newly diagnosed diabetes as determined
bythestandard2-h75-gOGTT.TheA1C
test did not distinguish between pre-
diabetic and normal subjects. Less than
30% of the newly diagnosed diabetes
couldbeidentiﬁedattheA1Ccutoffpoint
of 6.5%, the diagnostic benchmark rec-
ommended by the International Expert
Committee (7).
In previous studies, the optimal A1C
cutoff points for detecting undiagnosed
diabetes ranged from 5.3 to 6.1% in pop-
ulation-based studies among Australian
and American populations (10–12). In
those studies the sensitivity varied from
63.2 to 86.0%, and the speciﬁcity ranged
from 82.8 to 97.4% at a given optimal
A1C cutoff point. In a study among Hong
KongChinesewhowerereferredtoahos-
pital for conﬁrmative testing for glucose
intolerance, an optimal A1C cutoff point
of 6.1% for detecting 2-h plasma glucose
11.1mmol/lwasreported,whichgavea
sensitivity of 77.5% and a speciﬁcity of
78.8% (13). This Hong Kong study was,
however, performed among a preselected
high-risk population of which close to
one-fourth of its participants were diag-
nosed as having diabetes. Moreover, the
diagnostic criteria for diabetes in the
HongKongstudywerealsodifferentfrom
those used in our study. The inconsis-
tency in performance of the A1C test
among studies may have been due to the
discrepancies in ethnicity, assay methods
for A1C, the gold standard for diagnosis
of diabetes, study methodology differ-
Table 2—Characteristics of male and female subjects according to A1C level and diabetes status deﬁned by the OGTT
Undiagnosed diabetes Nondiabetes
A1C 6.5% A1C 6.5% A1C 6.5% A1C 6.5%
Male subjects (n  986)
n (%) 37 (3.8) 95 (9.6) 79 (8.0) 775 (78.6)
Age (years) 53.5 (50.456.6) 52.3 (50.354.2) 47.2 (44.949.4) 49.2 (48.550.0)
Waist circumference (cm) 89.3 (86.492.3) 88.5 (86.790.4) 86.8 (84.788.9) 86.9 (86.387.6)
BMI (kg/m
2) 26.3 (25.227.3) 26.2 (25.526.8) 25.7 (25.026.4) 25.6 (25.325.8)
Blood pressure (mmHg)
Systolic 138 (132145) 140 (136144) 135 (131139) 133 (131134)
Diastolic 91 (8794) 89 (8792) 88 (8591) 87 (8688)
Plasma glucose (mmol/l)
Fasting 9.8 (8.810.9) 7.2 (6.57.8)* 4.8 (4.75.0) 5.4 (5.35.4)*
2-h 17.3 (15.619.1) 10.5 (9.511.6)* 6.1 (5.86.5) 6.2 (6.16.4)
IGT and/or IFG 12 (15.2) 254 (32.8)†
FCG (mmol/l) 9.0 (8.39.7) 6.8 (6.47.2)* 6.0 (5.76.2) 5.8 (5.85.9)
Cholesterol (mmol/l) 5.7 (5.46.1) 5.5 (5.35.7) 5.4 (5.25.6) 5.2 (5.15.3)
Triglycerides (mmol/l)§ 1.5 (1.21.8) 1.4 (1.31.7) 0.9 (0.81.1) 1.2 (1.21.2)*
HDL cholesterol (mmol/l) 1.68 (1.531.84) 1.59 (1.491.68) 1.75 (1.641.85) 1.63 (1.591.66)‡
HOMA-IR§ 1.3 (0.81.9) 1.8 (1.42.4) 0.8 (0.71.0) 1.0 (0.91.1)
HOMA-B§ 19.7 (13.328.9) 41.7 (32.553.4)† 70.0 (58.384.0) 57.6 (53.861.7)
Female subjects (n  1,346)
n (%) 32 (2.4) 114 (8.5) 105 (7.8) 1,095 (81.4)
Age (years) 55.9 (52.659.2) 53.9 (52.255.7) 46.7 (44.948.5) 48.9 (48.349.4)‡
Waist circumference (cm) 88.1 (85.291.0) 85.3 (83.886.8) 84.1 (82.485.8) 81.2 (80.781.7)†
BMI (kg/m
2) 27.4 (26.328.5) 27.0 (26.427.6) 25.8 (25.226.5) 25.7 (25.425.9)
Blood pressure (mmHg)
Systolic 138 (130147) 143 (139148) 133 (129137) 131 (129132)
Diastolic 86 (8290) 88 (8691) 85 (8287) 84 (8384)
Plasma glucose (mmol/l)
Fasting 9.2 (8.69.9) 7.0 (6.67.3)* 4.8 (4.64.9) 5.5 (5.45.5)*
2-h 17.8 (16.319.2) 11.6 (10.812.3)* 6.7 (6.47.0) 6.7 (6.66.7)
IGT and/or IFG 23 (21.9) 400 (36.5)†
FCG (mmol/l) 9.8 (9.210.5) 6.8 (6.57.2)* 6.0 (5.86.2) 5.9 (5.85.9)
Cholesterol (mmol/l) 6.0 (5.66.4) 5.6 (5.45.8) 5.0 (4.85.2) 5.2 (5.15.3)‡
Triglycerides (mmol/l)§ 1.5 (1.21.8) 1.4 (1.31.6) 0.9 (0.91.0) 1.0 (1.01.1)‡
HDL cholesterol (mmol/l) 1.58 (1.411.75) 1.59 (1.491.68) 1.77 (1.691.85) 1.68 (1.661.71)
HOMA-IR§ 2.3 (1.73.0) 2.4 (2.02.8) 1.0 (0.91.2) 1.4 (1.31.5)*
HOMA-B§ 25.6 (19.034.5) 49.5 (42.258.1)* 98.3 (84.6114.2) 68.7 (65.272.4)*
Data are age-adjusted means (95% CI) or n (%). *P  0.001; †P  0.01; ‡P  0.05, for the difference between the indexed and the A1C 6.5% category within the
same glucose tolerance class of undiagnosed diabetes or nondiabetes using a univariate general linear model for continuous data and 
2 test for categorical data.
§Geometric mean (95% CI). With missing data.
Performance of A1C for detecting diabetes
548 DIABETES CARE, VOLUME 33, NUMBER 3, MARCH 2010 care.diabetesjournals.orgences (population-based versus clinical
based), and the prevalence of other risk
factors such as obesity. The extent to
which these factors affect the perfor-
mance of the A1C needs to be further in-
vestigated. However, our results are
consistent with other studies showing
that the A1C test did not detect IGT
(11,14,15).
Few studies have evaluated the per-
formance of the FCG test. In a randomly
selectedpopulation-basedstudyinBrazil,
the optimal FCG cutoff point for undiag-
nosed diabetes was 5.6 mmol/l, which
gave a sensitivity of 87.2% and a speciﬁc-
ity of 72.4% (16). Another study com-
pared FCG with A1C assays among
Caucasians who were referred to a hospi-
tal because they were suspected as having
diabetes (17). That study also showed
that the performance of the FCG test was
better than that of the A1C test in detect-
ing either diabetes or diabetes plus pre-
diabetes, which was similar to the
ﬁndings in our present study.
Prospective studies showed that ele-
vatedA1Cvaluesincreasetheriskofmor-
tality from all causes (18,19) and
cardiovasculardisease(19).Itwasalsore-
ported that A1C predicted mortality
(20,21)orincidentcardiovasculardisease
(22) depending largely on either the 2-h
plasma glucose (20–22) or the FPG (21)
levels. In our study, the blood pressure
and lipid levels in individuals with A1C
6.5% did not differ from those with
A1C 6.5%. However, both of these pa-
rameterswerehigherfordiabeticandpre-
diabetic individuals than they were for
normal subjects as deﬁned by the OGTT.
The prognosis of those individuals with
A1C 6.5% needs to be further investi-
gated in prospective studies.
The large number of individuals in-
cluded in this population-based study
Figure 1—ROC curve for A1C and FCG to assess the presence of newly diagnosed diabetes (NDM) and pre-diabetes in men (A) and women (B).
Table 3—Sensitivity and speciﬁcity corresponding to the optimal cutoff values of A1C and FCG for detecting newly diagnosed diabetes,
pre-diabetes, and newly diagnosed diabetes plus pre-diabetes in male and female subjects
Optimal cutoff point
NDM Pre-diabetes NDM  pre-diabetes
Sensitivity Speciﬁcity Sensitivity Speciﬁcity Sensitivity Speciﬁcity
Male subjects
A1C (%)
5.6 for NDM 64.4 61.6 33.5 59.4 43.7 59.4
6.5 (diagnostic criteria)* 28.0 90.5 4.5 88.3 12.3 88.3
FCG (mmol/l)
6.3 for NDM 72.0 68.4 46.6 75.2 55.0 75.2
6.0 for pre-diabetes 78.8 55.5 60.5 62.8 66.6 62.8
6.1 for NDM  pre-diabetes 75.0 61.0 55.6 68.5 62.1 68.5
Female subjects
A1C (%)
5.6 for NDM 62.3 63.3 36.2 62.9 42.9 62.9
6.5 (diagnostic criteria)* 21.9 91.2 5.7 89.4 9.8 89.4
FCG (mmol/l)
6.6 for NDM 65.1 77.0 34.8 83.4 42.5 83.4
6.1 for pre-diabetes and NDM 
pre-diabetes 73.3 59.2 56.7 67.8 61.0 67.8
Data are %. *Adopted as the diagnostic criteria for diabetes (7). NDM, newly diagnosed diabetes.
Zhou and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 3, MARCH 2010 549provided our study with high statistical
powerfordataanalyses.Diabetesandpre-
diabetes were deﬁned according to the
currentlyacceptedstandardcriteriabased
on both FPG and 2-h plasma glucose lev-
els. All individuals included in the analy-
sis provided data on FCG and A1C in
addition to the OGTT. These individuals
also yielded data on lipid and insulin,
which enabled us to study further the
clinical phenotypes of individuals of dif-
ferent glycemic categories. Because of the
strict inclusion criteria for glucose and
other variables, only 55% of the popula-
tion who had A1C measurements were
included in the data analyses. To check
whether the results have been biased by
the strict inclusion criteria, a sensitivity
analysis using all data available for the
A1C was made. The results of the sensi-
tivity analysis showed that the study was
less likely to be biased by the strict inclu-
sion criteria applied in the study. The
high prevalence of diabetes observed in
this study reﬂects the recent increase in
the prevalence of diabetes in Qingdao,
which has been investigated in detail and
reported (23,24). The question as to
whether the result can be found in other
populationsremainstobeconﬁrmed.An-
otherlimitationofourstudyisthathemo-
globin concentrations were not available,
and, thus, a potential inﬂuence of condi-
tions such as hemolytic anemia and he-
moglobinopathies on A1C assays cannot
be excluded. Nevertheless, these condi-
tions are rare in the general population
from which our study population was
drawn. The prevalence of abnormal he-
moglobin in the Shandong province in
which Qingdao is located is only 0.04%
(25).
Insummary,asamassscreeningtool,
the FCG test performed better than the
A1CtestinthegeneralpopulationofChi-
nese. In consideration of its high cost and
poor performance, the A1C test is not a
suitable test for mass screening, particu-
larly with the purpose of detecting pre-
diabetes for early intervention.
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